Vaccine adjuvant ginsenoside Rg1 enhances immune responses against hepatitis B surface antigen in mice

Canadian Journal of Physiology and Pharmacology

Volumn 94, Issue 6, 2016, Pages 676-681

  Yuan, Ding ^a   Yuan, Qin ^a   Cui, Qianqian ^a   Liu, Chaoqi ^a   Zhou, Zhiyong ^a   Zhao, Haixia ^a   Dun, Yaoyan ^a   Wang, Ting ^a   Zhang, Changcheng ^a  

^a CHINA THREE GORGES UNIVERSITY   (China)

Author keywords

Cell immunity; Ginsenoside Rg1; Hepatitis B surface antigen (HBsAg); Humoral immunity; Immune adjuvant

Indexed keywords

GAMMA INTERFERON; GINSENOSIDE RG 1; HEPATITIS B SURFACE ANTIGEN; HEPATITIS VACCINE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2B; INTERLEUKIN 4; MESSENGER RNA; TOLL LIKE RECEPTOR 4; GINSENOSIDE; HEPATITIS B VACCINE; IMMUNOLOGICAL ADJUVANT;

ADAPTIVE IMMUNITY; ADJUVANT THERAPY; ANIMAL EXPERIMENT; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION; HEPATITIS B; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; INNATE IMMUNITY; LIMIT OF QUANTITATION; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SPLEEN CELL; ANIMAL; BAGG ALBINO MOUSE; BLOOD; CELLULAR IMMUNITY; DRUG EFFECTS; IMMUNOLOGY;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; FEMALE; GINSENOSIDES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; IMMUNITY, CELLULAR; MICE; MICE, INBRED BALB C;

EID: 84970983729     PISSN: 00084212     EISSN: 12057541     Source Type: Journal    
DOI: 10.1139/cjpp-2015-0528     Document Type: Article

References (16)

1. Avramidis, N., Victoratos, P., Yiangou, M., and Hadjipetrou-Kourounakis, L. 2002. Adjuvant regulation of cytokine profile and antibody isotype of immune responses to Mycoplasma agalactiae in mice. Vet. Microbio. 88: 325–338. doi:10.1016/S0378-1135(02)00128-1. PMID:12220808.
2. Cooper, C.L., Davis, H.L., Morris, M.L., Efler, S.M., Adhami, M.A., Krieg, A.M., et al. 2004. CPG 7909, an immune-stimulatory TLR9 agonist oligodeoxy nucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: a double-blind phase I/II study. J. Clin. Immunol. 24: 693–701. doi:10.1007/s10875-004-6244-3. PMID: 15622454.
3. Jeong, E.J., Maeng, H.J., Lee, H.J., Kim, Y., and Kim, C.K. 2012. Effect of adjuvant on pharmacokinetics, organ distribution and humoral immunity of hepatitis B surface antigen after intramuscular injection to rats. Arch. Pharm. Res. 35: 1621–1628. doi:10.1007/s12272-012-0913-1. PMID:23054719.
4. Kawase, O., Goo, Y.K., Jujo, H., Nishikawa, Y., and Xuan, X. 2011. Starfish, Asterias amurensis and Asterina pectinifera, as potential sources of Th1 immunitystimulating adjuvants. J. Vet. Med. Sci. 73: 227–229. doi:10.1292/jvms.10-0163. PMID:20847539.
5. Levie, K., Gjorup, I., Skinhoj, P., and Stoffel, M. 2002. A 2-dose regimen of a recombinant hepatitis B vaccine with the immune stimulant AS04 compared with the standard 3-dose regimen of Engerix-B in healthy young adults. Scand. J. Infect. Dis. 34: 610–614. doi:10.1080/00365540110080881. PMID:12238579.
6. Mahboubi, A., Fazeli, M.R., Samadi, N., Dinarvand, R., and Azadi, S. 2012. Evaluation of thimerosal removal on immunogenicity of aluminum salts adjuvanted recombinant hepatitis B vaccine. Iran. J. Pharm. Res. 11: 39–46. PMID: 25317183
7. Oh, D.R., Kang, H.W., Kim, J.R., Kim, S., Park, I.K., Rhee, J.H., et al. 2014. PMA induces vaccine adjuvant activity by the modulation of TLR signaling pathway. Mediators. Inflamm. 2014: 406514. 8 p. doi:10.1155/2014/406514. PMID: 24948847.
8. Orr, M.T., Beebe, E.A., Hudson, T.E., Moon, J.J., Fox, C.B., Reed, S.G., et al. 2014. A dual TLR agonist adjuvant enhances the immunogenicity and protective efficacy of the tuberculosis vaccine antigen ID93. PLoS One, 9: e83884. doi:10.1371/journal.pone.0083884. PMID:24404140.
9. Pouliot, K., Buglione-Corbett, R., Marty-Roix, R., Montminy-Paquette, S., West, K., Wang, S., et al. 2014. Contribution of TLR4 and MyD88 for adjuvant monophosphoryl lipid A (MPLA) activity in a DNA prime-protein boost HIV-1 vaccine. Vaccine, 32: 5049–5056. doi:10.1016/j.vaccine.2014.07.010. PMID:25045815.
10. Qu, D.F., Yu, H.J., Liu, Z., Zhang, D.F., Zhou, Q.J., Zhang, H.L., et al. 2011. Ginsenoside Rg1 enhances immune response induced by recombinant toxoplasma gondii SAG1 antigen. Vet. Parasitol. 179: 28–34. doi:10.1016/j.vetpar.2011.02.008. PMID:21439733.
11. Shima, F., Uto, T., Akagi, T., and Akashi, M. 2013. Synergistic stimulation of antigen presenting cells via TLR by combining CpG ODN and poly(γ -glutamic acid)-based nanoparticles as vaccine adjuvants. Bioconjug. Chem. 24: 926–933. doi:10.1021/bc300611b. PMID:23631730.
12. Sobol, P.T., Boudreau, J.E., Stephenson, K., Wan, Y., Lichty, B.D., and Mossman, K.L. 2011. Adaptive antiviral immunity is a determinant of the therapeutic success of oncolytic virotherapy. Mol. Ther. 19: 335–344. doi:10.1038/mt.2010.264. PMID:21119618.
13. Su, F., Yuan, L., Zhang, L., and Hu, S. 2012. Ginsenosides Rg1 and Re act as adjuvant via TLR4 signaling pathway. Vaccine, 30: 4106–4112. doi:10.1016/j.vaccine.2012.03.052. PMID:22472794.
14. Su, F., Xue, Y., Wang, Y., Zhang, L., Chen, W., and Hu, S. 2015. Protective effect of ginsenosides Rg1 and Re on LPS-induced sepsis by competitive binding to toll-like receptor 4. Antimicrob. Agents. Chemother. 59: 5654–5663. doi:10.1128/AAC.01381-15. PMID:26149990.
15. Tarantino, G., Savastano, S., Capone, D., and Colao, A. 2011. Spleen: a new role for an old player? World. J. Gastroenterol. 17: 3776–3784. doi:10.3748/wjg.v17.i33.3776. PMID:21987619.
16. Yan, X., Maixner, D.W., Yadav, R., Gao, M., Li, P., Bartlett, M.G., et al. 2015. Paclitaxel induces acute pain via directly activating toll like receptor 4. Mol. Pain. 11: 10. doi:10.1186/s12990-015-0005-6. PMID:25868824.